psychedelics

Question 1

Gordis 2015

Answer 1

epidemiology - study how diseases spread through the population

Question 2

randomised controlled treatment

Answer 2

active treatment-assess outcome variable-comparator (placebo)

Question 3

Jones 2000

Answer 3

injection of insulin , treatment of psychosis - 88% improvement rate (RCT used drug. placebo) no evidence of long term impact after 6 months

Question 4

Positron emission tomography

Answer 4

radio active injection that binds to D 1 receptors

Question 5

clear 2013

Answer 5

SSRI impact on depression 16% difference in results

Question 6

Fallon 2017

Answer 6

methyl phenidate..>double blind Placebo , improves ignoring/ impairs updating

Question 7

madsen 2019

Answer 7

effects of psilocybin- PET scans-5 H T 2 A agonists

Question 8

SSRI’s

Answer 8

blocks re-uptake of serotonin

Question 9

psychedelics

Answer 9

stimulates serotonergic receptor

Question 10

Griffiths 2006

Answer 10

meenylphenidate+ psilocybin , psilocybin -greater impact (more crying, joy, peace)- rated top 5 life experiences

Question 11

depression

Answer 11

not a binary state

Question 12

Grob 2011

Answer 12

psilocybin on anxiety after 6 months- reduction in depression symptoms

Question 13

Carhart-Harris 2016

Answer 13

treatment resistant depression-psilocybin decrease in QlD’s score at 2/3 weeks- increase at 5 weeks

Question 14

Hanakieva 2019

Answer 14

same amount of time perceived as longer post-LSD dose

Question 15

carhart- Harris 2016

Answer 15

psilocybin reduces depressive symptoms more than escitalopram

Question 16

Daws 2022

Answer 16

SSRI don’t always change communication in brain regions

Question 17

Rootman 2021

Answer 17

microdosing group (more alcohol+ drugs) but reduced anxiety, depression

Question 18

khan+ Brown 2013

Answer 18

placebo vs. SSRI’s placebo rated highest symptom reduction

Question 19

limitations of micro-dosing

Answer 19

little evidence that it benefits cognition or mood